In 2010, the US FDA approved the use of Lucentis intravitreal injections for macular edema (sometimes occurs for a few days or weeks after surgery); then in 2013, the National Institute for Health and Care Excellence in the UK also approved it to be used for the treatment of macular edema caused by diabetes and/or retinal vein occlusion.
In 2010, the US FDA approved the use of Lucentis intravitreal injections for macular edema. Macular edema sometimes occurs for a few days or weeks after cataract surgery, but most such cases can be successfully treated with NSAID or cortisone eye drops. In 2013 Lucentis by intravitreal injection was approved by the National Institute for Health and Care Excellence in the UK for the treatment of macular edema caused by diabetes and/or retinal vein occlusion. 
